Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Aurinia Pharmaceuticals Inc. AUPH (the "Company") today announced that members of the senior management team will participate in the H.C. Wainwright & Co. 23rd Annual Global Investment Conference, September 13-15, 2021. The Aurinia presentation will be available on-demand beginning September 13, 2021 at 3 pm ET.

The audio webcast is available here. Interested parties can also register and access the presentation under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia's website.

ABOUT AURINIA

Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company recently introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis (LN). Aurinia's head office is in Victoria, British Columbia; its U.S. commercial hub is in Rockville, Maryland; and the Company focuses development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210910005494/en/